Research Advances Hold Promise for Multiple Myeloma Treatment

SOG_2118_13-2

Multiple myeloma is one of the most compelling examples of a cancer in which research has markedly improved the length and quality of patients’ lives in the last decade. A malignancy of certain white blood cells in the bone marrow known as plasma cells, myeloma is still considered incurable, but treatment advances have significantly improved survival. Not long ago, patients with myeloma lived a median time of two to three years after diagnosis. Today, median survival is seven to 10 years, although this can be unpredictable, with some patients living longer and others surviving for significantly shorter time periods. Scientists have …

Continue reading

How a Port Can Make Cancer Treatments Easier

4.14.14 PortSmall

For more than five years, Sally Boyd had repeated needle punctures in her arm for blood draws, chemotherapy, and other procedures for multiple myeloma. “The nurses said I had good veins, so at first it was easy for them to insert the needle,” Boyd recalls. “But as time went on, my arms were bruised and sore.” Dana-Farber has led the way in introducing new therapies that have transformed this type of blood cancer from a fatal disease to a chronic illness. However, living with multiple myeloma or other types of cancer often calls for procedures involving needles. Today, Boyd has …

Continue reading

A History of Multiple Myeloma Advances

Not long ago, a diagnosis of multiple myeloma — a cancer of the bone marrow — carried with it a very poor prognosis, with median survival estimates of just two to three years. Now, thanks in large part to research and treatment advances at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), this disease is for many patients a chronic, and more manageable disease, with prognosis now improved to median survivals of seven to ten years. Here is a look at how DF/BWCC physician-scientists and patients have helped lead the way toward improved treatment for multiple myeloma over the past three decades.

How Donated Blood and Platelets Help Cancer Patients

If you’ve ever donated blood or platelets, there’s a reasonable chance that your donation went to help a cancer patient. That’s because cancer and certain treatments can damage blood cells, which means some patients may need transfusions of one or more types of blood components:

What’s the Difference Between Donating Bone Marrow and Donating Stem Cells?

Stem cell transplantation (sometimes called bone marrow transplants) is a treatment for certain forms of cancer, such as leukemia, lymphoma, and multiple myeloma, as well as other diseases. But before a patient can receive a transplant, stem cells must be collected from a donor (an allogeneic donation) or from the patient (an autologous transplant).

New Therapies Bring Progress Against Multiple Myeloma

By Christine Cleary  The 21st century has seen great strides in treatment for multiple myeloma, a cancer of the bone marrow once considered a death sentence. In fact, thanks to research by Dana-Farber scientists, this blood cancer that took the lives of Geraldine Ferraro and Leonard P. Zakim has become a chronic disease for many patients.

Seven Tips for Life After Stem Cell Transplant

By Maria Pearson As a technology teacher who had a long career with IBM before going into education, I have encountered all sorts of opportunities to teach – and to learn. The biggest such opportunity of my life occurred at the intersection of cancer, technology, and Dana-Farber. In August 2010, I was diagnosed with stage III multiple myeloma, a blood cancer. No search engine was adequate in comforting my fears of life expectancy, treatment, or facing a stark life-altering challenge.

Making Science Count: A Conversation with Ken Anderson

When Ken Anderson, MD, began working on multiple myeloma four decades ago, the disease, a cancer of the bone marrow, was untreatable. “People died within months,” says Anderson. Today, the story is very different. In the past decade, eight new multiple myeloma treatments have been approved. Survival has doubled. “When we see new patients, we can look them in the eye and say it’s likely you will live a decade or longer with modern therapies,” says Anderson, who recently received a 2012 Medal of Honor award from the American Cancer Society for his contributions to these advancements. “And that’s continuing …

Continue reading